Novovax COVID-19 vaccine, more traditional type, now available in Michigan
The Novavax vaccine, a more traditional type that does not use mRNA technology to fight COVID-19, is now available in Michigan. Some pharmacies and federally qualified health centers had the vaccine earlier because they received the vaccine through federal channels, Wuth reported. As of last week, when the state’s vaccine dashboard was last updated, about 80 people had received a dose of the Novavax vaccine in Michigan. Pfizer’s vaccine, first approved in late 2020, is the most administered vaccine in Michigan, where about 58% of residents are fully vaccinated against COVID-19. Most commonly reported side effects of the Novavax vaccine were fatigue, muscle pain, headache, joint pain, nausea and fever.
mlive.comNovavax cuts 2022 revenue guidance in half, stock tanks in after-hours trading
Novavax deeply cut its full year revenue guidance Monday as sales of its Covid-19 vaccine slowed significantly in the second quarter. The company cut its 2022 sales outlook by about 50% and now expects to generate $2 billion to $2.3 billion in revenue this year. Novavax previously forecast $4 billion to $5 billion in revenue for the year. The company posted a net loss of $6.53 per share and posted revenue of $186 million for the quarter, well below expectations. The Maryland biotech company's Covid-19 vaccine sales slowed to $55 million in the second quarter from nearly $585 million in the first part of the year.
cnbc.comWhat we know about the Novavax vaccine: Yahoo News Explains
U.S. regulators have granted emergency use authorization for a new COVID-19 vaccine developed by Novavax. Dr. Monica Gandhi, an infectious disease specialist and a professor of medicine at the University of California, San Francisco, explains what sets this new vaccine apart from the Pfizer-BioNTech and Moderna shots and how it could combat future variants.
news.yahoo.comWhen can you get the newly approved Novavax vaccine for COVID-19?
The United States added another weapon in the battle against COVID-19 this week when the CDC and FDA gave their blessing to roll out Novavax’s vaccine. So, with Novavax getting the green light, the question for those folks becomes when and where they can get their vaccination? Well, according to CBS News, states likely won’t be able to begin requesting shipments of the vaccine until next week. CBS News said that means that doctors offices and pharmacies likely won’t receive their first doses until sometime in August. It said part of the delay is that the company is just now wrapping up quality testing on its vaccine.
mlive.comNovavax’s more traditional COVID vaccine could combat hesitancy, doc says
Nearly one in every three Michiganders age 5 and older have not yet gotten a COVID-19 vaccine, despite ample supply, data and medical guidance indicating the benefits outweigh the risks. “It’s a more traditional option that’s going to be available for people who have been hesitant to get vaccinated,” Sullivan said. During clinical trials, the Novavax vaccine proved safe and about 90% effective at preventing symptomatic COVID-19. Dr. Sullivan knows adding another vaccine option is not going to convince all the remaining holdouts, but he said it could move the needle. About 66.3% of Michigan residents age 5 and older have gotten at least one dose of COVID-19 vaccine since late 2020.
mlive.comNew vaccine may be option for troops with religious concerns
A COVID-19 vaccine that could soon win federal authorization may offer a boost for the U.S. military: an opportunity to get shots into some of the thousands of service members who have refused the other coronavirus vaccines for religious reasons.
Novavax Covid vaccine clears key step on path to FDA authorization after committee endorses the shot
In this photo illustration the Food and Drug Administration (FDA) and Novavax logos are seen behind a medical syringe and vials. Novavax's shot would be the fourth Covid vaccine authorized for use in the U.S. The technology differs from Pfizer and Moderna's shots, which were the first ones using messenger RNA technology to receive FDA approval. Novavax, like every Covid vaccine, was designed to target the original strain of the virus that first emerged in Wuhan, China in 2019. Novava'x vaccine technology differs in a number of ways from Pfizer and Moderna's shots.
cnbc.comDrugmaker Novavax begins late-stage vaccine trial in UK
LONDON – U.S.-based Novavax has begun a late stage trial of its potential COVID-19 vaccine in the United Kingdom because the high-level of the coronavirus circulating in the country is likely to produce quick results, the pharmaceutical company said. Novavax plans to test the effectiveness of its vaccine in a trial involving 10,000 people between the ages of 18 and 84, according to a statement issued late Thursday. The trial is being conducted in partnership with the U.K. government’s Vaccine Taskforce, which was created in April to help speed the development of a COVID-19 vaccine. The U.K. has already agreed to buy 60 million doses of the Novavax vaccine to ensure it can be distributed as quickly as possible if it is approved by regulators. The government said Friday that participants in the Novavax trial will be drawn from the 250,000 people who have volunteered to take part in COVID-19 vaccine testing through the National Health Service’s Vaccine Registry.
Stocks post solid gains as technology shares lead rally
Despite the rally, the S&P 500 still posted its fourth straight weekly loss, extending Wall Street's September swoon. The S&P 500 rose 1.6% after flip-flopping between small gains and losses a few times in the early going. The S&P 500 came within striking distance of a 10% drop from its all-time high earlier this week, what Wall Street calls a correction. The S&P 500 rose 51.87 points to 3,298.46. Norwegian Cruise Line notched the biggest gain in the S&P 500, vaulting 13.7%.
The Latest: Concerns over coronavirus upticks in California
The directive comes amid concerns about an uptick in coronavirus cases in certain Brooklyn and Queens neighborhoods with large Orthodox Jewish populations. New York City’s current overall infection rate remains low, but official figures indicate the affected neighborhoods accounted for 20% of the city’s coronavirus cases in recent weeks. ___BOSTON — An outbreak of coronavirus infections at a major Boston hospital has grown to 19 confirmed cases. ___DES MOINES, Iowa — Iowa has reported a jump of 1,086 new coronavirus cases, the second consecutive day of new cases exceeding 1,000. There are currently nearly 985,000 worldwide coronavirus deaths.
Trump to visit North Carolina, cite work on COVID-19 vaccine
WASHINGTON The White House says President Donald Trump will visit North Carolina on Monday to tour a business that is participating in work on a COVID-19 vaccine. The White House said Trump is expected to speak about the collaboration between the administration and the private sector to rapidly develop a vaccine and ensure rapid distribution once ready. North Carolina is a key battleground state in the coming election, and Trumps visit marks his 10th trip to the state during his presidency. The biotechnology facility Trump will visit is the FUJIFILM Diosynth Biotechnologies Innovation Center in Morrisville, a suburb of Raleigh. The White House said the company is manufacturing key components of a COVID-19 vaccine candidate being developed by Novavax, an American vaccine development company based in Maryland.
US company trials coronavirus vaccine candidate in Australia
In this photo released by Nucleus Network/ABC, clinical trial participants are given a coronavirus vaccine in Melbourne, Australia, Tuesday, May 26, 2020, with hopes of releasing a proven vaccine this year. Novavax will inject 131 volunteers in the first phase of the trial testing the safety of the vaccine and looking for signs of its effectiveness. (Patrick Rocca/Nucleus Network/ABC via AP)CANBERRA A U.S. biotechnology company began injecting a coronavirus vaccine candidate into people in Australia on Tuesday with hopes of releasing a proven vaccine this year. Novavax used genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory. The way we make a vaccine is we never touch the virus, Novavax told The Associated Press last month.